Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma

Nutthasirikul,Nichapavee; Limpaiboon,Temduang; Leelayuwat,Chanvit; Patrakitkomjorn,Siriporn; Jearanaikoon,Patcharee

doi:10.3892/ijo.2013.1818

Ratio disruption of the ∆133p53 and TAp53 isoform equilibrium correlates with poor clinical outcome in intrahepatic cholangiocarcinoma

Authors:
- Nichapavee Nutthasirikul
- Temduang Limpaiboon
- Chanvit Leelayuwat
- Siriporn Patrakitkomjorn
- Patcharee Jearanaikoon
View Affiliations

Affiliations: Centre for Research and Development of Medical Diagnostic Laboratories, Faculty of Associated Medical Sciences; Liver Fluke and Cholangiocarcinoma Research Center, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand
Published online on: February 8, 2013 https://doi.org/10.3892/ijo.2013.1818
Pages: 1181-1188

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

All p53 family members are expressed in several isoforms through alternative promoters and alternative splicing. However, the significance of these isoforms is not yet well understood in cholangiocarcinoma (CCA). In this study, we investigated the expression of p53, p63, p73 and their isoforms at the mRNA and protein levels in CCA. The overexpression of ∆133p53 was observed in the CCA cell lines and clinical specimens. Moreover, the high expression of ∆133p53/TAp53 correlated with short overall survival (p<0.001). Defective p53, including mutant and ∆Np53, was associated with poor prognosis (p<0.024). Multivariate analysis demonstrated that ∆133p53̸TAp53 and mutant p53 protein may be used as independent prognostic factors for CCA. To our knowledge, this is the first report of the use of ∆133p53̸TAp53 as a potential biomarker in CCA.

View Figures

View References

1	Sripa B and Pairojkul C: Cholangiocarcinoma: lessons from Thailand. Curr Opin Gastroenterol. 24:349–356. 2008. View Article : Google Scholar : PubMed/NCBI
2	Blechacz B and Gores GJ: Cholangiocarcinoma: advances in pathogenesis, diagnosis, and treatment. Hepatology. 48:308–321. 2008. View Article : Google Scholar : PubMed/NCBI
3	Stiewe T: The p53 family in differentiation and tumorigenesis. Nat Rev Cancer. 7:165–168. 2007. View Article : Google Scholar
4	Murray-Zmijewski F, Lane DP and Bourdon JC: p53/p63/p73 isoforms: an orchestra of isoforms to harmonise cell differentiation and response to stress. Cell Death Differ. 13:962–972. 2006. View Article : Google Scholar : PubMed/NCBI
5	Mills AA, Zheng B, Wang XJ, Vogel H, Roop DR and Bradley A: p63 is a p53 homologue required for limb and epidermal morpho-genesis. Nature. 398:708–713. 1999. View Article : Google Scholar : PubMed/NCBI
6	Bourdon JC: p53 and its isoforms in cancer. Br J Cancer. 97:277–282. 2007. View Article : Google Scholar : PubMed/NCBI
7	Bourdon JC, Fernandes K, Murray-Zmijewski F, et al: p53 isoforms can regulate p53 transcriptional activity. Genes Dev. 19:2122–2137. 2005. View Article : Google Scholar : PubMed/NCBI
8	Marcel V, Perrier S, Aoubala M, et al: Δ160p53 is a novel N-terminal p53 isoform encoded by Δ133p53 transcript. FEBS Lett. 584:4463–4468. 2010.
9	Helton ES, Zhu J and Chen X: The unique NH2-terminally deleted (DeltaN) residues, the PXXP motif, and the PPXY motif are required for the transcriptional activity of the DeltaN variant of p63. J Biol Chem. 281:2533–2542. 2006. View Article : Google Scholar : PubMed/NCBI
10	Marchini S, Marabese M, Marrazzo E, et al: DeltaNp63 expression is associated with poor survival in ovarian cancer. Ann Oncol. 19:501–507. 2008. View Article : Google Scholar : PubMed/NCBI
11	Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW and Ngan HY: Expression of deltaNp73 and TAp73alpha independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res. 12:3922–3927. 2006. View Article : Google Scholar : PubMed/NCBI
12	Marabese M, Marchini S, Marrazzo E, et al: Expression levels of p53 and p73 isoforms in stage I and stage III ovarian cancer. Eur J Cancer. 44:131–141. 2008. View Article : Google Scholar : PubMed/NCBI
13	Müller M, Schilling T, Sayan AE, et al: TAp73/Delta Np73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ. 12:1564–1577. 2005.PubMed/NCBI
14	Soldevilla B, Díaz R, Silva J, et al: Prognostic impact of ΔTAp73 isoform levels and their target genes in colon cancer patients. Clin Cancer Res. 17:6029–6039. 2011.
15	Limpaiboon T, Sripa B, Wongkham S, Bhudhisawasdi V, Chau-in S and Teerajetgul Y: Anti-p53 antibodies and p53 protein expression in cholangiocarcinoma. Hepatogastroenterology. 51:25–28. 2004.PubMed/NCBI
16	Yang B, House MG, Guo M, Herman JG and Clark DP: Promoter methylation profiles of tumor suppressor genes in intrahepatic and extrahepatic cholangiocarcinoma. Mod Pathol. 18:412–420. 2005. View Article : Google Scholar : PubMed/NCBI
17	Lin Z, Nan Y, Zhang X, Zhao Y, Kim C and Kim I: Reverse transcription-polymerase chain reaction and western blotting analysis for detection of p63 isoforms in uterine cervical cancers. Int J Gynecol Cancer. 16:1643–1647. 2006. View Article : Google Scholar
18	Furubo S, Harada K, Shimonishi T, Katayanagi K, Tsui W and Nakanuma Y: Protein expression and genetic alterations of p53 and ras in intrahepatic cholangiocarcinoma. Histopathology. 35:230–240. 1999. View Article : Google Scholar : PubMed/NCBI
19	Song W, Huo SW, Lü JJ, et al: Expression of p53 isoforms in renal cell carcinoma. Chin Med J (Engl). 122:921–926. 2009.PubMed/NCBI
20	Fujita K, Mondal AM, Horikawa I, et al: p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol. 11:1135–1142. 2009. View Article : Google Scholar : PubMed/NCBI
21	Conforti F, Yang AL, Agostini M, et al: Relative expression of TAp73 and ΔNp73 isoforms. Aging (Albany, NY). 4:202–205. 2012.